Richardson P, Beksaç M, Oriol A, Lindsay J, Schjesvold F, Galli M, Yağcı M, Larocca A, Weisel K, Yu X, Donahue C, Acosta J, Peluso T, Dimopoulos M(2025) Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial Eur J Haematol(in press) DOI 10.1111/ejh.14365, PubMed 39777934
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau Pet al.(2024) Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma N Engl J Med(in press) DOI 10.1056/NEJMoa2409029, PubMed 39652675
Rosenberg T, Möller S, Abildgaard N, Nørgaard JN, Lysén A, Tsykonova G, Joao C, Vangsted A, Schjesvold F, Nielsen LK(2024) Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study Eur J Haematol(in press) DOI 10.1111/ejh.14358, PubMed 39638553